Antisense Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its produc… Read more
Antisense Therapeutics Limited (ATHJF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.287x
Based on the latest financial reports, Antisense Therapeutics Limited (ATHJF) has a cash flow conversion efficiency ratio of -0.287x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.68 Million) by net assets ($9.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Antisense Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Antisense Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Antisense Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Antisense Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bluerock Homes Trust Inc.
NYSE MKT:BHM
|
0.021x |
|
RTRZY
OTCGREY:RTRZY
|
N/A |
|
Shinyoung Waco
KO:005800
|
0.040x |
|
NexturnBioscience Co. Ltd
KQ:089140
|
0.019x |
|
Home Loan Financial Corp
PINK:HLFN
|
0.060x |
|
GameSquare Holdings Inc.
NASDAQ:GAME
|
-0.132x |
|
Iqstel Inc
OTCQX:IQST
|
-0.034x |
|
Garo AB
ST:GARO
|
0.070x |
Annual Cash Flow Conversion Efficiency for Antisense Therapeutics Limited (2002–2024)
The table below shows the annual cash flow conversion efficiency of Antisense Therapeutics Limited from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $9.36 Million | $-10.12 Million | -1.080x | -32.22% |
| 2023-06-30 | $9.98 Million | $-8.15 Million | -0.817x | -121.33% |
| 2022-06-30 | $21.14 Million | $-7.81 Million | -0.369x | +63.76% |
| 2021-06-30 | $5.73 Million | $-5.83 Million | -1.019x | -16.98% |
| 2020-06-30 | $4.53 Million | $-3.95 Million | -0.871x | +16.46% |
| 2019-06-30 | $2.81 Million | $-2.93 Million | -1.042x | -91.14% |
| 2018-06-30 | $4.22 Million | $-2.30 Million | -0.545x | +65.32% |
| 2017-06-30 | $1.85 Million | $-2.91 Million | -1.572x | -255.40% |
| 2016-06-30 | $4.58 Million | $-2.03 Million | -0.442x | -347.26% |
| 2015-06-30 | $7.09 Million | $1.27 Million | 0.179x | +112.01% |
| 2014-06-30 | $2.09 Million | $-3.11 Million | -1.489x | -144.27% |
| 2013-06-30 | $4.65 Million | $-2.83 Million | -0.610x | -33.48% |
| 2012-06-30 | $5.27 Million | $-2.41 Million | -0.457x | +50.63% |
| 2011-06-30 | $2.02 Million | $-1.87 Million | -0.925x | +6.96% |
| 2010-06-30 | $1.34 Million | $-1.34 Million | -0.994x | -18.94% |
| 2009-06-30 | $3.93 Million | $-3.28 Million | -0.836x | -55.71% |
| 2008-06-30 | $6.33 Million | $-3.40 Million | -0.537x | -20.59% |
| 2007-06-30 | $6.02 Million | $-2.68 Million | -0.445x | +1.08% |
| 2006-06-30 | $8.79 Million | $-3.96 Million | -0.450x | +12.43% |
| 2005-06-30 | $10.86 Million | $-5.59 Million | -0.514x | -298.62% |
| 2004-06-30 | $17.13 Million | $-2.21 Million | -0.129x | +57.16% |
| 2002-06-30 | $13.48 Million | $-4.06 Million | -0.301x | -- |